WEALTH DISCOVERY SECURITIES PVT. LTD. 1 Stock Details Industry Pharmaceuticals Bloomberg Code ARTD IN BSE Code 524348 Face Value (Rs.) 10.00 Market Cap. (Rs. Mn) 15,159.90 52wk. High/Low (Adjusted) ( (Rs.) 874.00/334.13 Shareholding Pattern Jun '15 Promoter (%) 59.96 FII (%) 0.15 DII (%) 2.06 Public - Other (%) 37.82 No. of Share Outstanding (mn) 24.22 Valuation Summary FY 14A FY 15A FY 16E FY 17E P/E (x)* 05 20 18 16 EV/EBITDA (x)* 1.57 9.81 9.10 8.27 P/BV (x)* 0.64 4.99 4.77 4.43 *Based On CMP on Reco Date for FY 15 and Market Price as on 1 st Apr is taken for FY14 Key Financial Rs. Mn FY 14A FY 15A FY 16E FY 17E Net Sales 9,717 10,872 12,871 15,442 EBITDA 1,473 1,696 2,071 2,503 Net Profit 617 776 985 1,223 EPS (Rs.)* 25.5 32.0 40.7 50.5 *Unadjusted for any bonus issue Key Ratios FY 14A FY 15A FY 16E FY 17E EBITDA Margin (%) 15.2 15.6 16.1 16.2 EBIT Margin (%) 12.3 12.8 13.4 13.7 Net Pro. Margin (%) 6.4 7.1 7.7 7.9 Debt/Equity (x) 0.31 0.50 0.31 0.27 RoNW (%) 26.9 28.0 29.2 30.0 RoCE (%) 17.7 17.8 19.0 21.2 Aarti Drugs 06 October 2015 Initiating Coverage (BUY) INR 626 INR 808 CMP Target Price We recommend 'BUY' on Aarti Drugs for a target of INR 808 - valuing the company at P/E of 16x FY17E Earning. Positioning high on both the domestic and global pharma industry: Aarti Drugs is engaged in manufacturing of high qualities APIs, Pharma Intermediates and specialty chemicals and highly positioned its products across domestic and international markets. Exports to over 97 countries with strong presence in regulated markets including Brazil, Mexico, Netherland & Spain and its Clientele includes MNCs viz. Abbott, Sanofi- Aventis, Merck, Teva, Searle, Pfizer, Bayer and Clariant. Exports constituting 38% of its revenues. The company's domestic clients comprise all major formulation companies like Cipla, Dr Reddy's, Cadilla, Ranbaxy, Glaxo, Alembic, etc. The company is the market leader in most of its top 10 products thereby enabling it to enjoy economies of scale. Over the last decade, the company has gained scale by growing its revenues from INR 2,000mn to over INR 10,000mn at an annual growth of ~16%. Driving profitability by focusing on high value products: Strategically allocating much of its incremental capex towards high value import substitute products in segments of Antibiotic, Antifungal, Cardio and Antidiabetic. These new products margin will be in line with those of other categories however owing to their higher realizations the company will be able to increase its asset turnover thereby driving the return ratios. Over the last few years, the company has increased its ROCE from 6.4% in FY12 to 17.4% in FY15 which we expect to rise to 21.2%/22.7% by FY17/18E. Planning rapid expansion to drive 19% revenue growth over FY15-17E: Planning to incur an annual capex of around INR 1,000mn in coming years to unfold the opportunities in domestic and global market. We expect the company to grow its revenues and profits at 19% and 21% respectively over FY15-17E. VALUATIONS AND VIEW: Given the visibility of high growth prospects in the long term with its strong product base ranging from API, Steroids, Pharma Intermediates and Speciality Chemicals, its position in the domestic and global pharmaceutical industry, aggressive expansion plans in high value segments, a 21% CAGR in profits over FY15-17E along with consistently expanding return ratios and dividend payout of 30%; we value the business at 16.0x FY17E EPS and recommend a BUY rating on the stock with a target price of INR 808 per share.
10
Embed
CMP Target Price - Wealth Discovery Group...client contributing to only 3.77% of total export sales Top ten export clients contributes to only 24.80% of total export sales Top ten
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
WEALTH DISCOVERY SECURITIES PVT. LTD. 1
Stock Details Industry Pharmaceuticals
Bloomberg Code ARTD IN
BSE Code 524348
Face Value (Rs.) 10.00
Market Cap. (Rs. Mn) 15,159.90
52wk. High/Low (Adjusted) ( (Rs.) 874.00/334.13
Shareholding Pattern Jun '15 Promoter (%) 59.96
FII (%) 0.15
DII (%) 2.06
Public - Other (%) 37.82
No. of Share Outstanding (mn) 24.22
Valuation Summary FY 14A FY 15A FY 16E FY 17E
P/E (x)* 05 20 18 16
EV/EBITDA (x)* 1.57 9.81 9.10 8.27
P/BV (x)* 0.64 4.99 4.77 4.43
*Based On CMP on Reco Date for FY 15 and
Market Price as on 1st Apr is taken for FY14
Key Financial Rs. Mn FY 14A FY 15A FY 16E FY 17E
Net Sales 9,717 10,872 12,871 15,442
EBITDA 1,473 1,696 2,071 2,503
Net Profit 617 776 985 1,223
EPS (Rs.)* 25.5 32.0 40.7 50.5
*Unadjusted for any bonus issue
Key Ratios FY 14A FY 15A FY 16E FY 17E
EBITDA Margin (%) 15.2 15.6 16.1 16.2
EBIT Margin (%) 12.3 12.8 13.4 13.7
Net Pro. Margin (%) 6.4 7.1 7.7 7.9
Debt/Equity (x) 0.31 0.50 0.31 0.27
RoNW (%) 26.9 28.0 29.2 30.0
RoCE (%) 17.7 17.8 19.0 21.2
Aarti Drugs
06 October 2015
Initiating Coverage (BUY)
INR 626
INR 808
CMP
Target Price
We recommend 'BUY' on Aarti Drugs for a target of INR 808 - valuing the
company at P/E of 16x FY17E Earning.
Positioning high on both the domestic and global pharma industry:
Aarti Drugs is engaged in manufacturing of high qualities APIs, Pharma Intermediates and specialty chemicals and highly positioned its products across domestic and international markets. Exports to over 97 countries with strong presence in regulated markets including Brazil, Mexico, Netherland & Spain and its Clientele includes MNCs viz. Abbott, Sanofi- Aventis, Merck, Teva, Searle, Pfizer, Bayer and Clariant. Exports constituting 38% of its revenues. The company's domestic clients comprise all major formulation companies like Cipla, Dr Reddy's, Cadilla, Ranbaxy, Glaxo, Alembic, etc. The company is the market leader in most of its top 10 products thereby enabling it to enjoy economies of scale. Over the last decade, the company has gained scale by growing its revenues from INR 2,000mn to over INR 10,000mn at an annual growth of ~16%. Driving profitability by focusing on high value products: Strategically allocating much of its incremental capex towards high value import substitute products in segments of Antibiotic, Antifungal, Cardio and Antidiabetic. These new products margin will be in line with those of other categories however owing to their higher realizations the company will be able to increase its asset turnover thereby driving the return ratios. Over the last few years, the company has increased its ROCE from 6.4% in FY12 to 17.4% in FY15 which we expect to rise to 21.2%/22.7% by FY17/18E. Planning rapid expansion to drive 19% revenue growth over FY15-17E: Planning to incur an annual capex of around INR 1,000mn in coming years to unfold the opportunities in domestic and global market. We expect the company to grow its revenues and profits at 19% and 21% respectively over FY15-17E. VALUATIONS AND VIEW: Given the visibility of high growth prospects in the long term with its strong product base ranging from API, Steroids, Pharma Intermediates and Speciality Chemicals, its position in the domestic and global pharmaceutical industry, aggressive expansion plans in high value segments, a 21% CAGR in profits over FY15-17E along with consistently expanding return ratios and dividend payout of 30%; we value the business at 16.0x FY17E EPS and recommend a BUY rating on the stock with a target price of INR 808 per share.
WEALTH DISCOVERY SECURITIES PVT. LTD. 2
RISK & CONCERNS:
Volatile Crude Oil Prices: Variation in crude oil prices would always be area of concern. Aarti Drugs Limited “ADL” has already
installed greener technologies like briquette fired boilers, economizers etc. to save power and fuel costs, which reflects in the
financial result of the Company. ADL was able to cope up with these pressures due to strong operational efficiency and increased
market share of its products.
Volatility of exchange rate: Extreme volatility of exchange rate of rupee against US dollar can have significant impact on ADL
operations because approximately 40% of its total revenues consist of exports. However, natural hedge mitigate the risk to large
extent due to the imports. ADL has a strict FOREX policy of hedging all of its foreign currency loans to mitigate the risk of volatility
of exchange rate.
Adverse pricing action under DPCO: Any action by the government under the DPCO (Drug Price Control Order) to add more drugs
under the price control mechanism could act as a dampener for the sector which could have an impact on the company as well.
However, since ADL has a basket of over 35 products, it shall be able to wither such an impact in case it were to happen.
Import alert: One of ADLs' Tarapur facility was issued an import alert in March 2015. However this won't have any major impact
on the company as US forms less than a percent of the company's revenue. Further, the import alert was issued due to data
integrity reasons as USFDA requires the minutest of details to be furnished. We believe the company follows robust manufacturing
practices as audits are carried out by its customers on one-third of the days on an average.
Q1 FY16 RESULT HIGHLIGHTS: Strong Revenue Growth in line with expectations:
Achieved a turnover of Rs. 2636.70 mn, a growth of 1.53% YoY for the 1st quarter of FY 2016 as against Rs. 25978.00 mn in the
corresponding quarter of the previous year. Revenues at this level do not portray the actual numbers. In an attempt to bifurcate
revenues between APIs, Intermediaries & Formulations, the company has set up a subsidiary where it shall transfer its formulations
business in a gradual manner. During the quarter, the company transferred INR ~250mn of formulations revenue to this subsidiary.
Adjusting for this transfer, the company achieved revenues of INR 2880mn (+11% YoY). Managements of the company already
indicated that the revenue impact of new capacity would kick in from 3QFY16 and thus 1H would remain flattish YoY, however the
performance of 1QFY16 has been a positive surprise.
In Q1 FY16, Net profit stood at Rs. 170.50 million from Rs. 172.30 million over the corresponding quarter last year. EBDITA stood
at Rs. 435.10 million compared to Rs. 398.50 million in the corresponding quarter of the previous year, rising by 9.18% YoY.
The company has reported an EPS of Rs. 7.04 for the 1st quarter as against an EPS of Rs. 14.23 in the corresponding quarter of the
previous year.
From 3QFY16 onwards it has plan to start the sale of high value products initially in the anti-diabetic segment viz. Metformin and
later in antibiotic and antiprotozoal segments and thus the company is likely to witness major growth in topline.
Disclaimer: This document has been prepared by Wealth Discovery Securities Private Limited (hereinafter referred to as WD) to provide information about the company(ies)
and/sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and
does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other
investments and Wealth Discovery Securities Private Limited (hereinafter referred as WD) is not soliciting any action based upon it. This report is not for public distribution and has
been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal
recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in
this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments
referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future
performance, future returns are not guaranteed and a loss of original capital may occur.
WD generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any
companies that the analysts cover. Additionally, WD generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member
of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to
our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are
inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to
real or potential conflicts of interest. WD and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position
in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and
earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such
company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have
no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the
affiliates of WD even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report Reports based on technical and derivative
analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may
not match with a report on a company's fundamental analysis. In addition WD has different business segments / Divisions with independent research separated by Chinese walls
catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors
and markets.
Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to
exempt WD or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold WD or any of its affiliates or employees
responsible for any such misuse and further agrees to hold WD or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered
by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable.
Any statements contained in this report attributed to a third party represent WD's interpretation of the data, information and/or opinions provided by that third party either
publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or
summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, WD and/or its
affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent WD and/or its affiliates from doing so.
WD or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this report. WD or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter
pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and noninfringement. The recipients of this report
should rely on their own investigations.
WD and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. Subject Company
may have been a client of WD or its associates during twelve months preceding the date of distribution of the research report WD and/or its affiliates and/or employees may have
interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this
report. To enhance transparency, WD has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views
expressed in the report.
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the
research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts,
strategists, or research associates principally responsible for preparation of WD research receive compensation based upon various factors, including quality of research, investor
client feedback, stock picking, competitive factors and firm revenues
Disclosure of Interest Statement Aarti Drugs
1.Analyst ownership of the stocks mentioned above No
2.Served as an officer, director or employee No
Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication,
availability or use would be contrary to law, regulation or which would subject WD & its group companies to registration or licensing requirements within such jurisdictions.